Novel antibodies and combined use of a treg depleting antibody and an immunostimulatory antibody
Novel antibodies and combined use of a treg depleting antibody and an immunostimulatory antibody
Described is the sequential administration of first a Treg depleting antibody mole- cute selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti- body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. De- scribed are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.
WO2019020774-A2
31 January 2019
Frendeus, Bjorn
3c6a6739-3319-4ae5-8019-d54470e2f444
Martensson, Linda
b2bfc6e1-efa5-4f34-9d56-f78b90accd17
Semmrich, Monika
913807d9-6ff8-424e-b616-ede82babb94c
Teige, Ingrid
203d3295-4d50-4067-aea7-c7f4e0be8d1a
Beers, Stephen
a02548be-3ffd-41ab-9db8-d6e8c3b499a2
Al-Shamkhani, Aymen
0a40b3ce-9d71-4d41-9369-7212f0a84504
Gray, Juliet
12d5e17c-97bb-4d6d-8fc4-3914b730ed42
Glennie, Martin
9f6f0eff-4560-48c2-80cd-0ec116110ded
Frendeus, Bjorn, Martensson, Linda, Semmrich, Monika, Teige, Ingrid, Beers, Stephen, Al-Shamkhani, Aymen, Gray, Juliet and Glennie, Martin
(Inventors)
(2019)
Novel antibodies and combined use of a treg depleting antibody and an immunostimulatory antibody.
WO2019020774-A2.
Abstract
Described is the sequential administration of first a Treg depleting antibody mole- cute selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti- body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. De- scribed are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.
This record has no associated files available for download.
More information
Published date: 31 January 2019
Identifiers
Local EPrints ID: 445129
URI: http://eprints.soton.ac.uk/id/eprint/445129
PURE UUID: 6cfc2fc4-0c20-455a-abef-4cc05701c3f7
Catalogue record
Date deposited: 20 Nov 2020 17:32
Last modified: 23 Jul 2022 01:51
Export record
Contributors
Inventor:
Bjorn Frendeus
Inventor:
Linda Martensson
Inventor:
Monika Semmrich
Inventor:
Ingrid Teige
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
